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ABSTRACT  62 
Background: The efficacy of NS5A inhibitors for the treatment of patients chronically infected 63 
with hepatitis C virus (HCV) can be affected by the presence of NS5A resistance-associated 64 
substitutions (RASs). We analyzed data from 35 phase 1, 2, and 3 studies in 22 countries to 65 
determine the pretreatment prevalence of various NS5A RASs, and their effect on outcomes of 66 
treatment with ledipasvir-sofosbuvir in patients with genotype 1 HCV.  67 
Methods: NS5A gene deep sequencing analysis was performed on samples from 5,397 patients 68 
in Gilead clinical trials. The effect of baseline RASs on sustained virologic response (SVR) rates 69 
was assessed in the 1,765 patients treated with regimens containing ledipasvir-sofosbuvir.  70 
Results: Using a 15% cut-off, pretreatment NS5A and ledipasvir-specific RASs were detected in 71 
13% and 8% of genotype 1a patients, respectively, and in 18% and 16% of patients with 72 
genotype 1b. Among genotype 1a treatment-naïve patients, SVR rates were 91% (42/46) vs 99% 73 
(539/546) with and without ledipasvir-specific RASs, respectively. Among treatment-74 
experienced genotype 1a patients, SVR rates were 76% (22/29) vs 97% (409/420) with and 75 
without ledipasvir-specific RASs, respectively. Among treatment-naïve genotype 1b patients, 76 
SVR rates were 99% for both those with and without LDV-specific RASs (71/72 vs 331/334) , 77 
and among treatment-experienced genotype 1b patients, SVR rates were 89% (41/46) vs 98% 78 
(267/272) for those with and without ledipasvir-specific RASs, respectively.      79 
Conclusions: Pretreatment ledipasvir-specific RASs that were present in 8%-16% of patients 80 
have an impact on treatment outcome in some patient groups in particular treatment-experienced 81 
patients with genotype 1a HCV.  82 
• Keywords: NS5A RAS, HCV genotype 1, ledipasvir-sofosbuvir 83 
 84 
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LAY SUMMARY 85 
The efficacy of treatments using NS5A inhibitors for patients with chronic Hepatitis C virus 86 
(HCV) infection can be affected by the presence of NS5A resistance-associated substitutions 87 
(RASs). We reviewed results from 35 clinical trials where patients with genotype 1 HCV 88 
infection received treatments that included ledipasvir-sofosbuvir to determine how prevalent 89 
NS5A RASs are in patients at baseline, and found that ledipasvir-specific RASs were present in 90 
8-16% of patients prior to treatment and had a negative impact on treatment outcome in subset of 91 
patient groups in particular treatment-experienced patients with genotype 1a HCV. 92 
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INTRODUCTION 93 
Due to high rates of viral replication and an error prone HCV RNA polymerase, tremendous 94 
variability of HCV has been observed within infected patients (quasispecies) with all single 95 
mutations that do not abolish viral replication thought to be pre-existing (1). As a result, NS5A 96 
RASs are observed at baseline in patients infected with chronic HCV. Deep sequencing enables 97 
detection of HCV substitutions, point deletions, or insertions within the quasispecies down to a 98 
frequency of 1%. However, commercially available assays based on standard population HCV 99 
sequencing or not cross-validated next generation, also called deep sequencing,  report variants 100 
with a frequency of ≥15% of the quasispecies.  101 
The prevalence of baseline NS5A RASs has been reported to be 6% to 16% using population 102 
sequencing (cut off 15-25%) or deep sequencing (cut off 1%) (2-4). Interestingly, the prevalence 103 
and type of baseline NS5A RASs may vary by geographic regions. For example, the prevalence 104 
of the NS5A M28V in genotype 1a-infected patients was shown to be higher in the United States 105 
than in Europe, 7% versus 0%, respectively (5). Furthermore, the prevalence of genotype 3 106 
NS5A Y93H varied between 0% and 17% in different geographic regions (6). A comparison of 107 
baseline prevalence of RASs in Japanese and Western patients showed that the prevalence of 108 
Q80L and S122G in NS3, and L28M, R30Q and Y93H in NS5A was significantly higher in 109 
Japanese patients than the Western counterparts (7). 110 
Many currently approved interferon (IFN)-free regimens for the treatment of chronic hepatitis C 111 
(HCV) include an inhibitor of HCV NS5A. To date, there are five NS5A inhibitors approved for 112 
treatment of chronic HCV infection; ledipasvir (LDV), daclatasvir, and velpatasvir (which are all 113 
administered with the NS5B inhibitor sofosbuvir), and ombitasvir (in a fixed-dose combination 114 
with the protease inhibitor paritaprevir, the nonnucleoside NS5B polymerase inhibitor dasabuvir, 115 
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and ritonavir, a potent inhibitor of CYP3A4 enzymes), and elbasvir (in a fixed-dose combination 116 
with the protease inhibitor grazoprevir) (8-12). The presence of baseline NS5A RASs may 117 
impact treatment outcome of some NS5A inhibitor containing HCV regimens due to the intrinsic 118 
qualities of the NS5A inhibitor, drug pharmacology, or effects of the other compounds within the 119 
treatment regimen. However, depending on how NS5A RASs are defined and included in 120 
resistance analysis, as well as what level of variant detection is utilized, different results may be 121 
obtained. To date, three definitions of NS5A variants that are associated with resistance have 122 
been used most commonly; polymorphisms at RAS positions (RAPs), class RASs, and drug-123 
specific RASs. Polymorphisms at RAS positions are defined as any change from reference 124 
sequence for a specific genotype at positions associated with NS5A inhibitor resistance. NS5A 125 
class RASs are substitutions that have been shown to emerge on treatment or confer a significant 126 
reduction in susceptibility in vitro (e.g., >2.5 fold change in EC50) to any approved or 127 
investigational NS5A inhibitor. Drug-specific RASs refer to substitutions that have been shown 128 
to emerge on the specific drug treatment or confer significantly reduced susceptibility in vitro to 129 
the specific NS5A inhibitor. In addition, drug-specific RASs can be categorized into groups with 130 
different levels of reduced susceptibility to the drug.  131 
To enable comparisons of resistance analyses between clinical trials, standardization of RAS 132 
definitions and sensitivity cut offs is needed. In several studies, population sequences were used 133 
for resistance analysis (cut off of variant detection 15%-25%) and NS5A polymorphisms at RAS 134 
positions were defined as RAPs. In these studies, the presence of baseline NS5A polymorphisms 135 
at RAS positions had shown no significant impact on treatment outcome (5, 12). Further study is 136 
needed to understand the role of RASs present at frequencies below 15% and whether 137 
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substitutions without an in vitro susceptibility change to the NS5A inhibitor may dilute a clinical 138 
signal by RASs that do confer reduced susceptibility to a specific NS5A inhibitor.   139 
Here, we characterized the prevalence of baseline NS5A RASs in 5,397 NS5A inhibitor-naïve 140 
patients infected with genotype 1a or 1b HCV according to geographic regions. Moreover, we 141 
assessed the effect of baseline NS5A RASs, defined as NS5A RAPs, NS5A class RASs or LDV-142 
specific RASs using 1% and 15% sensitivity of substitution detection cut offs, on treatment 143 
outcome among 1,765 patients treated with currently recommended regimens containing 144 
ledipasvir-sofosbuvir. A previous analysis using a portion of the same dataset has recently been 145 
published (13). That analysis concerned the prevalence and effect on treatment of NS3, NS5A, 146 
and NS5B RASs, and included data on patients who had been treated with regimens/durations 147 
that have not been incorporated into label recommendations or treatment guidelines. The current 148 
study covers only NS5A RASs and includes data only from patients who received guideline-149 
recommended regimens.  150 
 151 
MATERIAL AND METHODS 152 
Sequencing Analysis 153 
Deep sequencing of baseline plasma samples was performed in 5,397 patients from 22 countries 154 
across the HCV Gilead clinical development program from 2010 to 2015. The list of clinical 155 
trials and identification numbers are included in the supplement materials (supplemental Table 156 
1). The HCV NS5A coding regions were amplified by DDL Diagnostic Laboratory (Rijswijk, 157 
Netherlands) using proprietary amplification primers and standard reverse transcription 158 
polymerase chain reaction (RT-PCR) technology, if a plasma sample was available and baseline 159 
HCV RNA was >1000 IU/mL. Deep sequencing using MiSeq platform (Illumina, Inc., San 160 
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Diego, CA) was performed by WuXi AppTec (Shanghai, China) or DDL Diagnostic Laboratory 161 
(Rijswijk, Netherlands).  Deep sequencing data was split into one file per sample using only 162 
100% matched barcodes to bin the reads. Sequence analysis was performed using internally 163 
developed software in a stepwise fashion. Briefly, raw reads from the FASTQ files were trimmed 164 
and filtered based on quality scores and read length. Trimming was carried out on reads when 165 
quality score decreased below 15, and reads shorter than 50 nucleotides were removed. Deep 166 
sequencing data was aligned using MOSAIK v1.1.0017.  All aligned reads were then translated 167 
in-frame and changes from a reference sequence were determined.  Assay sensitivity and assay 168 
background cutoffs were evaluated based on plasmid and RNA controls. There are no 169 
standardized HCV deep sequencing assays available as commercialized kits, therefore cross-170 
validation of deep sequencing data from DDL and WuXi was performed on a subset of control 171 
samples. 172 
Ethics Statement 173 
All studies were conducted in accordance with the Declaration of Helsinki, Good Clinical 174 
Practice guidelines, and local regulatory requirements. All patients provided written informed 175 
consent. 176 
Definition of NS5A Polymorphisms at RAS Positions (RAPs) and Resistance-Associated 177 
Substitutions (RASs) 178 
NS5A RAPs were defined as any change from genotype 1a or 1b reference strains (1a-H77 or 179 
1b-Con1) at NS5A positions associated with NS5A drug resistance. NS5A class RASs were 180 
summarized by the HCV Drug Resistance Advisory Group group (14), and/or recently observed 181 
in clinical trials with ledipasvir, velpatasvir, daclatasvir, pibrentasvir, and elbasvir (15-23), 182 
specifically variants at NS5A positions 24, 28, 30, 31, 32, 38, 58, 92, 93 that confer >2.5-fold 183 
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reduced susceptibility to any NS5A inhibitor. Ledipasvir-specific RASs were classified as 184 
variants at NS5A positions 24, 28, 30, 31, 32, 38, 58, 92, 93 that confer >2.5-100 or >100-fold 185 
reduced susceptibility to ledipasvir in vitro or were selected in clinical trials in patients treated 186 
with ledipasvir-containing regimens (2, 24, 25) (Table 1).  187 
Assessment of Sustained Virologic Response (SVR) in patients with and without 188 
pretreatment NS5A Inhibitor RASs 189 
SVR12 rates were assessed only in the 1,765 patients who were treated with currently 190 
recommended regimens containing ledipasvir-sofosbuvir (according to AASLD/IDSA and EASL 191 
guidelines) in 15 phase 2 and phase 3 Gilead-sponsored clinical trials (supplemental table 2). 192 
Only patients who were not previously exposed to NS5A inhibitors were included in these 193 
analyses. Patients were excluded from these analyses if they did not achieve SVR due to non-194 
virologic failure (e.g., lost to follow up). The results were analyzed according to the 1% and 15% 195 
detection cut-offs of NS5A RAPs, class RASs or ledipasvir-specific RASs.  196 
 197 
RESULTS 198 
Patient Baseline Characteristics  199 
Demographic and baseline clinical characteristics of the 5,393 NS5A inhibitor-naive patients 200 
included in the NS5A baseline prevalence RAS analysis are provided in Table 2. The majority of 201 
patients were treatment naïve (56%) and male (64%), with HCV genotype 1a (65%) and non-CC 202 
interleukin (IL) 28B alleles (73%). Approximately one third (32%) of patients had cirrhosis.  203 
Prevalence and Type of Pretreatment RASs across Geographic Regions  204 
Baseline prevalence of NS5A polymorphisms at RAS positions, NS5A class RASs, ledipasvir 205 
RASs and the specific Y93H NS5A variant was evaluated in genotype 1a (n=3501) and 1b 206 
  
11 
 
(n=1887) patients using 1%  through 50% sensitivity cut-offs (Figure 1). Higher prevalence of all 207 
categories for NS5A RASs was observed at 1% sensitivity cut-offs and sharply declined with 208 
reduction in sensitivity of variant detection to 15%. No significant changes in NS5A RASs 209 
prevalence was observed with further reductions in assay sensitivity from 15% to 50%.  210 
The prevalence of NS5A polymorphisms at RAS positions was significantly higher as compared 211 
to NS5A  class RASs in both genotype 1a and 1b across all sensitivity cut-offs. The prevalence 212 
of NS5A class RASs was about 5% higher than that of LDV RASs in genotype 1a. This 213 
difference was mostly represented by prevalence of the M28V NS5A class RAS that is not an 214 
LDV RAS. There was little difference between NS5A class and LDV RASs in genotype 1b. 215 
Prevalence of Y93H was higher in genotype 1b as compared to genotype 1a across all assay cut 216 
offs. Based on the observation of a sharp decline in prevalence from 1% to 15%, further analyses 217 
were performed with both 1% and 15% cut-offs.   218 
Overall at the 15% assay cut off, pretreatment NS5A class RASs were detected in 13.0% of 219 
genotype 1a patients (Table 3). The prevalence of NS5A class RASs overall in patients with 220 
genotype 1a HCV did not differ significantly across most of the geographic regions with the 221 
frequency ranging from 12.1% to 15.6%, but the prevalence of ledipasvir RASs was significantly 222 
higher among patients in Oceania, than among those from other regions combined (12.7% vs 223 
7.9%, p=0.005). The overall prevalence of baseline ledipasvir RASs in genotype 1a patients was 224 
8.3% with some numeric differences between different regions, the highest in Oceania (12.7%) 225 
and the lowest in Europe (7.7%). Specific RASs were detected at a similar frequency in genotype 226 
1a patients across geographic regions, including K24R, M28V/T, Q30H/R, L31M and Y93H.  227 
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The overall prevalence of baseline NS5A class RASs was slightly higher (17.6%) in patients 228 
infected with genotype 1b than in those infected with genotype 1a (Table 3). The frequency of 229 
detection of NS5A class RASs ranged from 16.1% to 20.4% in genotype 1b patients with only 230 
minor numeric differences across geographic regions. The prevalence of baseline LDV RASs 231 
among genotype 1b patients was also similar across different regions (15.2-16.4%). Y93H was 232 
detected at a much higher frequency (10.6%) than other RASs, including L28M and L31I/M/V 233 
among genotype 1b patients, but differences in the prevalence of each RAS between regions 234 
were small. In both subtypes, the prevalence of multiple (≥2) RASs was low; ranging from 0 to 235 
3.8% in genotype 1a, and all less than 1.5% in genotype 1b.  236 
Assessment of the Effect of Baseline RASs on Treatment Outcome with Ledipasvir-237 
Sofosbuvir by RAS Categories and Sensitivity Cut offs 238 
To evaluate the effect of baseline RASs on treatment outcome, SVR12 rates were assessed in 239 
1,765 patients from 15 ledipasvir-sofosbuvir clinical trials who were treated with currently 240 
recommended regimens according to the 2015 AASLD/IDSA and EASL guidelines. The 241 
baseline characteristics of this population are given in Table 4. A systematic comparison of the 242 
effect on SVR12 rates was performed in genotype 1a and 1b treatment-naive and treatment-243 
experienced patients for NS5A RAPs, class RASs, and LDV RASs, and LDV RASs with >100-244 
fold change, using a 15% sequencing assay cut off (Figure 2).  245 
In treatment-naive patients with genotype 1b HCV infection, the presence of baseline NS5A 246 
polymorphisms at RAS positions or NS5A class RASs did not impact the treatment outcome 247 
with ledipasvir-sofosbuvir regimens with SVR12 rates of 98%-99% in every group. The SVR12 248 
rate in genotype 1a patients with baseline LDV RASs was 94% and 91% (1% and 15% cut offs, 249 
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respectively) compared to 99% in patients without LDV RASs (Table 5). The presence of 250 
baseline LDV RASs in genotype 1b patients had no impact on SVR12 rates.   251 
In treatment-experienced patients with genotype 1a or 1b HCV infection, LDV RASs had the 252 
most notable impact on SVR12 rates (76%-80% vs 97%-98% and 89%-91% vs. 98% in 253 
genotype 1a and 1b, respectively). Even though similar results were obtained when 1% and 15% 254 
sensitivity assay cut offs were used, SVR12 rates were slightly lower when 15% assay cut off 255 
was used.   256 
Taken together, the comparison of the different categories of NS5A RASs and assay cut offs, 257 
LDV RASs detected with a 15% assay cut off was identified as the most discriminating for 258 
ledipasvir-sofosbuvir regimen baseline analyses and this cut off was used to perform further 259 
subgroup evaluations. 260 
Effect of Baseline Ledipasvir RASs on Treatment Outcome by Patient Population 261 
SVR12 rates by treatment history and cirrhosis status according to baseline ledipasvir RASs 262 
using a 15% assay cutoff was performed for HCV genotype 1a and genotype 1b (Figure 3) 263 
infected patients. The SVR12 rate in treatment-naïve non-cirrhotic patients was not substantially 264 
impacted by the presence of ledipasvir RASs at baseline (92% SVR). Numerically lower SVR12 265 
rates (86%) were observed in treatment-naïve cirrhotic genotype 1a patients with baseline 266 
ledipasvir RASs but only 7 patients limits the interpretability of this finding. Of genotype 1a 267 
patients, prior exposure to HCV treatment appeared to impact the SVR12 rates in both non-268 
cirrhotic and cirrhotic groups (75% and 77% respectively) in the presence of baseline ledipasvir 269 
RASs, but the number of patients in these groups was also small (<20). Of genotype 1b patients, 270 
the SVR12 rates remained >90% across the groups regardless of treatment history and presence 271 
  
14 
 
of cirrhosis with or without baseline ledipasvir RASs, except for the treatment-experienced non-272 
cirrhotic group which showed an SVR rate of 87%, but it only included 23 patients. The number 273 
and prevalence of patients with multiple RASs were small (N <30, <1%) for both ledipasvir-274 
specific and NS5A class RASs in genotype 1a and 1b. The overall SVR rates were 64% (9/14) in 275 
genotype 1a and 100% (2/2) in genotype 1b patients with multiple ledipasvir RASs 276 
(supplemental Table 3). Of those with multiple NS5A class RASs, the SVR rates were 74% 277 
(17/23) and 83% (5/6) among genotype 1a and 1b, respectively (supplemental Table 3).  278 
Among patients with cirrhosis, there were too few patients with baseline RASs to further assess 279 
the impact of treatment duration and/or the addition of ribavirin on treatment outcome 280 
(supplemental Table 4).  281 
DISCUSSION 282 
Current NS5A inhibitors show overlapping but distinct resistance profiles with RASs described 283 
at the NS5A amino acid positions 24, 28, 30, 32, 31, 38, 58, 92, and 93. There are advantages 284 
and disadvantages with each of the three main approaches to defining NS5A RASs. The 285 
advantage of using the NS5A RAPs definition is that it provides a uniform list of variants for all 286 
NS5A inhibitors. It does not require extensive phenotypic testing of all variants with several 287 
NS5A inhibitors and provides inclusive assessment of variants that developed in patients treated 288 
with NS5A inhibitors. However, for baseline analyses that investigate the role of pre-existing 289 
variants on treatment outcome, substitutions that are fully susceptible to a specific NS5A 290 
inhibitor dilute the investigated effect. To characterize NS5A class RASs, i.e. those that show 291 
reduced susceptibility to one or more NS5A inhibitors in vitro, standardized phenotypic testing is 292 
needed for each NS5A inhibitor. Even though the NS5A class RAS definition would exclude 293 
variants that are known to be sensitive to NS5A inhibitors and thus provide a more sensitive 294 
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analysis of the effect of baseline RASs on SVR, some attenuation of the signal may still be 295 
observed due to different resistance profiles among the NS5A inhibitors. With further 296 
optimization of NS5A inhibitors to improve resistance profiles, the list of NS5A variants and 297 
positions that confer reduced susceptibility to the next generation drugs is shortening. Using 298 
drug-specific RASs is the most scientifically rigorous way to perform efficacy and baseline 299 
resistance analyses. However, extensive standardized phenotypic testing is needed to accurately 300 
define drug-specific RASs. Additionally, novel resistance substitutions that develop rarely in 301 
vivo may be missed during resistance monitoring and it may be difficult to compare results to 302 
those from other studies since drug-specific RASs will be different between various NS5A 303 
inhibitors. Another disadvantage of using drug-specific RASs is that this definition fails to 304 
capture relevant information regarding the response in patients with resistance to other NS5A 305 
inhibitors.   306 
The results presented here show that analysis of ledipasvir drug-specific RASs shows more 307 
impact on ledipasvir-sofosbuvir treatment outcomes overall as compared to the analysis of RAPs 308 
or class RASs, as would be predicted based on these RASs having demonstrated reductions in 309 
susceptibility to ledipasvir. However the presence of drug-specific RASs may affect SVR12 rates 310 
to a greater or lesser extent depending on the specific pharmacology of an inhibitor and the drug 311 
combination regimen being utilized for treatment. For example, previous analyses of ledipasvir-312 
sofosbuvir clinical trials have shown that only ledipasvir-specific RASs contributing >100-fold 313 
reduction in susceptibility result in lower SVR rates with ledipasvir-sofosbuvir regimens (2).  314 
As multiple options for HCV treatment containing NS5A inhibitors have become available and 315 
more broadly applicable, understanding the prevalence of baseline NS5A RASs in specific 316 
regions has become more important. In this comprehensive analysis using >5,000 patient 317 
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samples from 21 countries in 4 continents, it is shown that the prevalence of both NS5A class 318 
and ledipasvir RASs does not differ significantly across regions for both genotype 1a and 1b. 319 
Numerically lower prevalence of NS5A RASs is observed for genotype 1a in Asia Pacific, but 320 
there were small numbers of genotype 1a patients included from this region (n=27) for 321 
epidemiological reasons. The prevalence of specific NS5A class and ledipasvir RASs is also 322 
similar across regions for both genotypes 1a and 1b. For genotype 1b, the prevalence of Y93H 323 
was the highest in Asia Pacific whereas the prevalence of L31M/I/V was the lowest in this 324 
region. It must be noted, however, that large regions of the world—including much of Asia, and 325 
all of Africa, South America and the Caribbean—are not represented in this analysis.  326 
The rates of SVR among patients without pretreatment ledipasvir RASs at all detections 327 
thresholds were high regardless of subtype and treatment history, ranging from 97% to 99%. The 328 
greatest impact of ledipasvir RASs on SVR was among treatment-experienced patients with 329 
genotype 1a HCV, who had an SVR rate of 76% (at the 15% cut-off). This difference was 330 
approximately the same at all detection thresholds. Among treatment-naïve patients with 331 
genotype 1b HCV, pretreatment ledipasvir RASs appeared to have little to no impact on SVR, 332 
with rates ranging from 98-99% for all detection thresholds. Treatment-naïve patients with 333 
genotype 1a HCV and treatment-experienced patients with genotype 1b HCV fell somewhere in 334 
between, with differences of 4% to 10% between those with and without ledipasvir RASs. 335 
The clinical interpretation of these findings remains challenging. The decision to perform pre-336 
treatment RAS testing may be made based on the magnitude of the effect of these RASs on 337 
treatment outcome. The effect of NS5A or ledipasvir-specific RASs on treatment outcome was 338 
greatest in treatment-experienced patients and/or those with cirrhosis, groups that are at highest 339 
risk of disease progression. An argument in favor of pre-treatment RAS testing could thus be 340 
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made, with the decision to possibly extend treatment duration and/or add ribavirin for those with 341 
ledipasvir-specific RASs. However, it should be noted that the number of patients within these 342 
subgroups was small (≤23 patients) and these data may not be generalizable to the broader 343 
population.  344 
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Figure Legends 451 
 452 
Figure 1. Prevalence of RASs According to Sensitivity Threshold. The figures show the 453 
prevalence of polymorphisms at RAS positions (RAPs), NS5A class RASs, ledipasvir-specific 454 
RASs, and the Y93H RAS by sensitivity threshold. Figure 1A shows prevalence in patients with 455 
genotype 1a HCV. Figure 1B shows prevalence in patients with genotype 1b HCV. 456 
 457 
Figure 2. SVR rates in patients with and without NS5A RASs. The figures show the rates of 458 
SVR12 by presence at baseline of NS5A polymorphisms at RAS positions (RAPs), NS5A class 459 
RASs, and ledipasvir-specific RASs, and ledipasvir-specific RASs that confer >100-fold change 460 
at a 15% sensitivity threshold.  461 
 462 
Figure 3. SVR12 rates by treatment history and cirrhosis status. The figures show the rates 463 
of SVR12 by regimen, treatment history (naïve vs previously treated), and cirrhosis status 464 
(present vs absent). NC = non-cirrhotic, C = cirrhotic, TE = treatment-experienced, and TN = 465 
treatment-naïve. 466 
  467 
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Table 1. List of NS5A Class RASs and Ledipasvir RASs 468 
 469 
GT 
Reference 
AA NS5A 
Position 
NS5A Class RASs LDV RASs 
Substitutions that 
confer >2.5 fold 
change in EC50 to any 
NS5A inhibitor 
Substitutions that confer 
>2.5-100 fold change in 
EC50 to ledipasvir (FC) 
Substitutions that confer 
>100 fold change in EC50 to 
ledipasvir (FC) 
1a 
K24 G/N/R G /(43), N (28), /R (4) -- 
M28 A/G/T/V T (61) A/G (>1000) 
Q30 C/E/G/H/I/K/L/R/S/T/Y L /(4), T (4) E/G/H/K /(>1000),  R (632) 
L31 F/I/M/V F (60) I /(370), M (554), /V (683) 
P32 L -- L (348) 
S38 F F (54) -- 
H58 D/L -- D (>1000) 
A92 K/T T (15) K (>1000) 
Y93 C/F/H/L/N/R/S/T/W F (7) C/H/N/S (>1000) 
1b 
Q24 - - -- 
(L28) M  -- 
R30 - - -- 
L31 F/I/M/V F /(8), I /(29), M /(3), V (43) 
-- 
P32 L L (8) -- 
S38 - - -- 
P58 D -- D (238) 
A92 K -- K (>1000) 
Y93 C/H/N/S C (5) H /(>1000),N /(110), S (142) 
FC = Fold Change 470 
 471 
472 
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Table 2. Patient Demographics and Baseline Characteristics 473 
 N. America 
(n= 3437) 
Europe 
(n= 972) 
Oceania 
(n= 387) 
Asia Pacific 
(n= 597) 
Total 
(n= 5393) 
Median age, years (range) 56 (18-81) 54 (18-80) 56 (22-74) 57 (20-80) 56 (18-81) 
Male, n (%) 2322 (68) 610 (63) 272 (70) 268 (45) 3472 (64) 
Race, n (%) 
White 2571 (80) 945 (97) 329 (85) 27 (5) 4052 (75) 
Black 579 (17) 14 (1) 0 0 593 (11) 
Asian 44 (1) 10 (1) 24 (6) 570 (96) 648 (12) 
Other 34 (1) 3 (<1) 14 (4) 0 51 (<1) 
Median BMI, kg/m2 (range) 27 (17-66) 25 (17-57) 27 (18-57) 24 (16-42) 27 (16-66) 
Genotype, n (%) 
1a 2635 (77) 531 (55) 314 (81) 27 (5) 3507 (65) 
1b 802 (23) 441 (45) 73 (19) 570 (95) 1886 (35) 
Median HCV RNA, log10 IU/mL 
(range) 
6.5 (1.4-8.0) 6.4 (3.2-8.0) 6.4 (1.9-7.7) 6.7 (3.7-7.6) 6.5 (1.4-8.0) 
Prior HCV treatment, n (%) 
Treatment-naïve 1961 (57) 559 (58) 184 (48) 332 (56) 3036 (56) 
Non-responder 756 (22) 217 (22) 105 (27) 86 (14) 1164 (22) 
Relapse/breakthrough 659 (19) 180 (19) 97 (25) 144 (24) 1080 (20) 
Other 61 (2) 16 (2) 1 (<1) 35 (6) 113 (2) 
IL-28B, n (%)* 
CC 790 (23) 215 (22) 130 (34) 324 (54) 1459 (27) 
CT 1922 (56) 568 (59) 197 (51) 247 (41) 2934 (55) 
TT 697 (20) 187 (19) 59 (15) 26 (4) 969 (18) 
Cirrhosis  1002 (29) 410 (42) 184 (48) 127 (21) 1723 (32) 
Median ALT (range), U/L 60 (9-578) 61 (7-420) 66 (12-494) 50 (11-619) 60 (7-619) 
*IL28B genotype was determined by sequencing of the rs12979860 single-nucleotide polymorphism. 474 
 475 
 476 
  477 
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Table 3. Prevalence of NS5A RASs in Patients Naïve to Treatment with NS5A Inhibitors by 478 
Region (15% cut off) 479 
 480 
Geno-
type RAS N. America Europe Oceania Asia Pacific Overall 
1a 
N 2635 531 314 27† 3507 
K24R None 1.5% 1.6% ND 1.1% 
M28T None 1.1% 2.5% ND 1.1% 
M28V 5.9% 4.7% 4.1% ND 5.4% 
Q30H 1.8% None 2.2% ND 1.7% 
Q30R None 1.7% 2.2% ND 1.1% 
L31M None 2.2% 4.1% ND 2.3% 
Y93H 1.0% None None ND None 
Any LDV RASs 7.9% 7.7% 12.7% ND 8.3% 
Any NS5A RASs 12.9% 12.1% 15.6% ND 13.0% 
1b 
N 802 441 73 570 1886 
L28M None 1.6% None 5.4% 2.4% 
L31M 5.9% 4.8% 2.3% 2.1% 4.3% 
L31I None None 5.5% None None 
Y93H 9.4% 10.2% 9.6% 12.8% 10.6% 
Any LDV RASs 15.5% 15.2% 16.4% 16.0% 15.6% 
Any NS5A RASs 16.1% 16.8% 16.4% 15.6% 17.6% 
- N. America included USA, Canada and Puerto Rico; Europe included Austria, Belgium, Switzerland, Czech 481 
Republic, Germany, Spain, France, United Kingdom, Italy, Netherlands and Poland; Asia Pacific included China, 482 
India, Japan, Korea, Russia and Taiwan; Oceania included Australia and New Zealand 483 
- Only variants with prevalence >1% are listed 484 
- No LDV-specific RASs were observed at NS5A positions (26), 32, 38, 58, and 92 with prevalence >1% 485 
-Prevalence of NS5A class RASs that are not LDV RASs are shown in parenthesis 486 
-*Prevalence of Y93H was not included in this table due to low prevalence in genotype 1a. Prevalence of Y93H was 487 
0.6%, 0.9%, and 0.9% in Europe, Oceania, and overall, respectively 488 
†The number of patients in the Asia Pacific region with genotype 1a HCV was too small to be the basis for 489 
prevalence estimates. 490 
 491 
  492 
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Table 4. Patient Demographics and Baseline Characteristics 493 
 N. America 
(n= 1103) 
Europe 
(n= 264) 
Oceania 
(n= 67) 
Asia Pacific 
(n= 331) 
Total 
(n= 1765) 
Mean age, years (range) 53 (22, 78) 55 (18, 77) 55 (40, 72) 57 (20, 80) 54 (18, 80) 
Male, n (%) 795 (72) 165 (63) 50 (75) 140 (42) 1150 (65) 
Race, n (%)      
White 817 (74) 258 (98) 50 (75) 0 1125 (64) 
Black 251 (23) 5 (2) 0 0 256 (15) 
Asian 15 (1) 1 (<1) 6 (9) 331 (100) 353 (20) 
Other 20 (2) 0 11 (16) 0 31 (1) 
Mean BMI, kg/m2 (range) 28 (18, 66) 25 (18, 40) 29 (18, 50) 24 (17, 38) 27 (17, 66) 
Genotype, n (%)      
1a 829 (75) 139 (53) 51 (76) 17 (5) 1036 (59) 
1b 271 (25) 124 (47) 16 (24) 313 (95) 724 (41) 
1 (no confirmed subtype) 3 (<1) 1 (<1) 0 1 (<1) 5 (<1) 
Mean HCV RNA, log10 IU/mL (range) 6.4 (1.4, 7.8) 6.4 (3.7, 7.5) 6.3 (4.9, 7.7) 6.6 (3.7, 7.6) 6.4 (1.4, 7.8) 
Treatment-naïve 682 (62) 135 (51) 28 (42) 178 (54) 1023 (58) 
Treatment-experienced 421 (38) 129 (49) 39 (58) 153 (46) 742 (42) 
IL-28B, n (%)*      
CC 239 (22) 41 (16) 24 (36) 203 (61) 507 (29) 
CT 626 (57) 166 (63) 27 (41) 119 (36) 938 (53) 
TT 238 (22) 57 (22) 15 (23) 9 (3) 319 (18) 
Cirrhosis  263 (24) 175 (66) 45 (67) 56 (17) 539 (31) 
Mean ALT (range), U/L 75 (9, 557) 82 (13, 344) 100 (27, 494) 66 (11, 619) 75 (9, 619) 
*IL28B genotype was determined by sequencing of the rs12979860 single-nucleotide polymorphism. 494 
 495 
  496 
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Table 5. SVR12 Rates in Patients with and without LDV RASs Using Various Sensitivity 497 
Thresholds 498 
 499 
Genotype Cut-off 
Treatment-naïve Treatment-experienced 
With LDV RASs No LDV RASs With LDV RASs No LDV RASs 
Patients with 
genotype 1a HCV 
1% 94% (84/89) 99% (497/503) 80% (44/55) 98% (387/394) 
2% 93% (68/73) 99% (513/519) 78% (35/45) 98% (396/404) 
5% 92% (57/62) 99% (524/530) 77% (27/35) 98% (404/414) 
7% 92% (55/60) 99% (526/532) 77% (27/35) 98% (404/414) 
10% 90% (46/51) 99% (535/541) 76% (22/29) 97% (409/420) 
15% 91% (42/46) 99% (539/546) 76% (22/29) 97% (409/420) 
25% 93% (38/41) 99% (543/551) 77% (20/26) 97% (411/423) 
50% 94% (34/36) 98% (547/556) 76% (19/25) 97% (412/424) 
Patients with 
genotype 1b HCV 
1% 99% (102/103) 99% (300/303) 91% (63/69) 98% (245/249) 
2% 99% (97/98) 99% (305/308) 90% (57/63) 98% (251/255) 
5% 99% (85/86) 99% (317/320) 88% (46/52) 98% (262/266) 
7% 99% (78/79) 99% (324/327) 88% (42/48) 99% (266/270) 
10% 99% (75/76) 99% (327/330) 87% (41/47) 99% (267/271) 
15% 99% (71/72) 99% (331/334) 89% (41/46) 98% (267/272) 
25% 98% (62/63) 99% (340/343) 88% (36/41) 98% (272/277) 
50% 98% (48/49) 99% (354/357) 85% (28/33) 98% (280/285) 
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Figure 1. Prevalence of RASs According to Sensitivity Threshold 
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Figure 2. SVR rates in patients with and without NS5A RASs 
 
 
 
 
 
 
 
 
  
Figure 3. SVR12 Rates by Treatment History and Cirrhosis State 
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